-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Acadia Pharmaceuticals, Raises Price Target to $38

Benzinga·11/05/2026 18:19:32
Listen to the news
RBC Capital analyst Brian Abrahams maintains Acadia Pharmaceuticals (NASDAQ:ACAD) with a Outperform and raises the price target from $36 to $38.